Abstracts tagged "COVID-19"

Abstract Number: 0826 • ACR Convergence 2021
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Miao Wang¹, Sylvie Lardeux², Elisea Avalos-Reyes³, Michele Hamburger⁴ and Kjel Johnson⁵, ¹CVS Health, New York, NY, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Lincoln, RI
Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…
Abstract Number: 0990 • ACR Convergence 2021
Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
Roxanne Cooksey¹, Mark Atkinson² and Ernest Choy³, ¹Cardiff University, Cardiff, Wales, United Kingdom, ²Swansea University, Swansea, Wales, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: The COVID-19 pandemic has caused over 3 million deaths. Having inflammatory arthritis (IA) and anti-rheumatic medications increase the risk of infections. Comorbidities, common in…
Abstract Number: 1430 • ACR Convergence 2021
Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19
Yu Zuo¹, Srilakshmi Yalavarthi¹, Sherwin Navaz¹, Claire Hoy¹, Alyssa Harbaugh¹, Kelsey Gockman¹, Melanie Zuo¹, Jacqueline Madison¹, Hui Shi¹, Yogendra Kanthi² and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²NHLBI, NIH, Bethesda, MD
Background/Purpose: The release of neutrophil extracellular traps (NETs) by hyperactive neutrophils is recognized to play an important role in the thromboinflammatory milieu inherent to severe…
Abstract Number: 1541 • ACR Convergence 2021
Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19
Shirkhan Amikishiyev¹, Mehmet Guven Gunver², Murat Bektas¹, Sarvan Aghamuradov¹, Burak Ince¹, Nevzat Koca¹, Ege Sinan Torun¹, Numune Aliyeva¹, Selma Sari¹, Cigdem Cetin³, Banu Cicek Yalcin Dulundu¹, Rabia Deniz⁴, Fatih Kemik⁴, Besim Fazil Agargun⁴, Ubeyde Ayse Gulseren⁴, Beliz Besisik⁴, Onur Alkan⁴, Ceren Bağrıaçık⁴, Yavuz Burak Tor⁴, Naci Senkal⁴, Yunus Catma⁴, Gorkem Durak⁵, Sevim Mese⁶, Ali Agacfidan⁶, Murat Kose⁴, Mustafa Erelel⁷, Arif Atahan Çağatay⁸, Sevgi Kalayoglu Besısık⁹, Figen Esen⁷ and Ahmet Gül¹⁰, ¹Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ²Department of Biostatistics, Istanbul Medical Faculty, İstanbul, Turkey,, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ⁵Istanbul Faculty of Medicine, Istanbul University, Department of Radiology, İstanbul, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Department of Medical Microbiology, Division of Virology and Fundamental Immunology, İstanbul, Turkey, ⁷Istanbul Faculty of Medicine, Istanbul University, Department of Anesthesiology, İstanbul, Turkey, ⁸Istanbul Faculty of Medicine, Istanbul University, Department of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey, ⁹Istanbul Faculty of Medicine, Istanbul University, Division of Hematology and Therapeutic Apheresis Unit, İstanbul, Turkey, ¹⁰Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: COVID-19 runs a severe disease associated with acute respiratory distress syndrome in a subset of patients, and a hyperinflammatory response developing in the second…
Abstract Number: 1559 • ACR Convergence 2021
Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India
Arun Tiwari¹, Suma Balan², Abdul Rauf³, Mahesh kappanayil², Sajith Kesavan², Suchitra Sivadas², Pranav Chickermane², Ajay Vijayan², Manu Raj², Anilkumar V² and Abish Sudhakar², ¹Amrita Institute of Medical Sciences, Ernakulam, India, ²Amrita Institute of Medical Sciences, Kochi, India, ³Baby Memorial Hospital, Kozikode, India
Background/Purpose: COVID-19 related multisystem inflammatory syndrome in children (MIS-C) has varied clinical presentation ranging from fever with mild gastrointestinal and/or mucocutaneous changes to life threatening…
Abstract Number: 1601 • ACR Convergence 2021
Satisfaction with Telemedicine in Immunosuppressed Children and Young Adults with Autoimmune Disease During the COVID 19 Pandemic: Are Their Needs Really Met? Preliminary Data from a Single Institution
Lakshmi Moorthy¹, Lauren Freidenrich¹, Lisa Mikesell², Sarah Fadem², Vikram Bhise¹, Richard Brodsky¹, Ellen Cahill¹, Joann Carlson¹, Yue Hao¹, Daniel Horton¹, Vivien Hsu¹, Editt Rodriguez¹, Christian Salazar³, Cynthia Salvant¹ and Lawrence Kleinman¹, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Department of Communication, New Brunswick, NJ, ³NYU Dept. of Epi. and Health Promotion, New York, NY
Background/Purpose: COVID-19 can lead to severe and life-threatening complications, which is particularly unnerving for patients with autoimmune disease (AID) on immunosuppressive therapy. Telemedicine has enabled…
Abstract Number: 1630 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Lauren Covert¹, Mara Becker², Rebecca Sadun¹ and Heather Van Mater¹, ¹Duke University, Durham, NC, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…
Abstract Number: 0087 • ACR Convergence 2021
TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries
Zara Izadi¹, Erica Brenner², Satveer Mahil³, Nick Dand⁴, Zenas Yiu⁵, Mark Yates⁴, Ryan Ungaro⁶, Xian Zhang², Manasi Agrawal⁶, Jean-Frederic Colombel⁷, Milena Gianfrancesco¹, Kimme Hyrich⁵, Anja Strangfeld⁸, Loreto Carmona⁹, Elsa Frazão Mateus¹⁰, Saskia Lawson-Tovey⁵, Eva Klingberg¹¹, Giovanna Cuomo¹², Marta Caprioli¹³, Rene-Marc FLIPO¹⁴, Ana Rita Cruz-Machado¹⁵, Carolina Mazeda¹⁶, Rebecca Hasseli¹⁷, Alexander Pfeil¹⁸, Hanns-Martin Lorenz¹⁹, Laura Trupin²⁰, Stephanie Rush¹, Patricia Katz¹, Gabriela Schmajuk¹, Lindsay Jacobsohn²¹, Andrea Seet¹, Samar Al Emadi²², Leanna Wise²³, Emily Gilbert²⁴, Ali Duarte-Garcia²⁵, Maria Valenzuela-Almada²⁶, Carolina Isnardi²⁷, Rosana Quintana²⁷, Enrique Soriano²⁸, Tiffany Hsu²⁹, Kristin D'Silva³⁰, Jeffrey Sparks³¹, Naomi Patel³⁰, Viviane de Souza³², Licia Maria Henrique Mota³³, Ana Paula Reis³⁴, Zachary S. Wallace³⁵, Suleman Bhana³⁶, Wendy Costello³⁷, Rebecca Grainger³⁸, Jonathan Hausmann³⁹, Jean Liew⁴⁰, Emily Sirotich⁴¹, Paul Sufka⁴², Philip Robinson⁴³, Pedro Machado⁴⁴, Christopher Griffiths⁴⁵, Jonathan Barker⁴, Catherine smith⁴, Jinoos Yazdany¹ and Michael Kappelman², ¹University of California San Francisco, San Francisco, CA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³St John’s Institute of Dermatology, London, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷MD, New York, NY, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ¹⁰Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹¹University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ¹²Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy, ¹³IRCCS Humanitas Research Hospital, Milan, Italy, ¹⁴Rheumatology Department, Lille University Hospital, Lille, France, ¹⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁶Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ¹⁷Justus-Liebig-University Giessen, Bad Nauheim, Germany, ¹⁸Friedrich Schiller University Jena, Jena, Germany, ¹⁹University Hospital Heidelberg Germany, Heidelberg, Germany, ²⁰UC San Francisco, San Francisco, CA, ²¹University of California San Francisco, Antioch, CA, ²²Hamad medical corporation, Doha, Qatar, ²³LAC+USC/Keck Medicine of USC, Pasadena, CA, ²⁴Mayo Clinic, Jacksonville, FL, ²⁵Mayo Clinic, Rochester, MN, ²⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ²⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²⁹Brigham and Women's Hospital, Jamaica Plain, MA, ³⁰Massachusetts General Hospital, Boston, MA, ³¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³²UFJF, JUIZ DE FORA, Brazil, ³³Universidade de Brasília, Brasilia, Brazil, ³⁴Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³⁵Harvard Medical School, Boston, MA, ³⁶Crystal Run Health, Montvale, NJ, ³⁷Irish Children's Arthritis Network, Bansha, Ireland, ³⁸University of Otago, Wellington, New Zealand, ³⁹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴⁰Boston University, Boston, MA, ⁴¹McMaster University, Hamilton, ON, Canada, ⁴²HealthPartners, Eagan, MN, ⁴³University of Queensland School of Clinical Medicine, Brisbane, Australia, ⁴⁴Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁴⁵University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) are widely prescribed globally due to their high efficacy across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19…
Abstract Number: 0105 • ACR Convergence 2021
Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization
Rachel Higgins¹, Hedley Hamilton², Michael Weisman³, John Reveille⁴, Kimbery Ogle¹, Cassie Shafer⁵, Elin Aslanyan⁵, Richard Howard⁵, Dongseok Choi¹, James T. Rosenbaum⁶ and Kevin Winthrop¹, ¹Oregon Health & Science University, Portland, OR, ²Any-3 Ltd, London, United Kingdom, ³Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Spondylitis Association of America, Encino, CA, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) remain at an increased risk of morbidity and mortality from vaccine preventable infections, often as a result…
Abstract Number: 0267 • ACR Convergence 2021
Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, S Sam Lim² and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Disruptions of routines or livelihood and worry during the COVID-19 pandemic may have impacted systemic lupus erythematosus (SLE) patients in multiple ways. We explored…
Abstract Number: 0856 • ACR Convergence 2021
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
Alexander Hall¹, Michael Trevisonno¹, Elizabeth Murray¹, Omoakhe Tisor¹, Emily Stanford¹, Jacob Gaines¹, Noor Anvery¹ and Ellen Ginzler², ¹SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
Abstract Number: 1013 • ACR Convergence 2021
SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children
Kate Webb¹, Thandeka Moyo-Gwete², Simon Mendelsohn³, Claire Butters⁴, Simone Richardson⁵, Heidi Facey-Thomas⁴, Debbie Abrahams⁴, Mashudu Madzivhandila⁵, Zanele Makhado⁵, Frances Ayres⁵, William Horsnell⁶, Neilia Manamela⁵, Richard Baguma³, Stanley Kimbung Mbandi³, Mzwandile Erasmus³, Thomas Scriba³, Liesl Zühlke⁷, Penny Moore⁵, George Kassiotis⁸ and Christiaan Scott⁴, ¹Paediatric Rheumatology University of Cape Town/ Francis Crick Institute, Cape Town, South Africa, ²National Institute of Communicable Diseases/University of Witwatersrand, Johannesburg, South Africa, ³South African TB vaccine initiative, IIDM, University of Cape Town, Cape Town, South Africa, ⁴Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ⁵National Institute of Communicable Diseases/University of Witwatersrand, Cape Town, South Africa, ⁶University of Cape Town, Cape Town, South Africa, ⁷Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, ⁸Retroviral Immunology, Francis Crick Institute, London, United Kingdom
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a severe disease that affects a small proportion of children exposed to Severe Acute Respiratory Syndrome Coronavirus…
Abstract Number: 1445 • ACR Convergence 2021
Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
Namrata Singh¹, Chen Hu², Vithal Madhira², Kate Fitzgerald², Timothy Bergquist³, Kayte Anderson², Amy Olex⁴, Rena Patel⁵ and Jasvinder Singh⁶, ¹University of Washington, Bellevue, WA, ²Johns Hopkins, Baltimore, MD, ³Sage Bionetworks, Seattle, WA, ⁴Virginia Commonwealth University, Richmond, VA, ⁵UW, Seattle, WA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…
Abstract Number: 1542 • ACR Convergence 2021
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
Andrew Laster¹, Gordon Lam¹, Sarah McCarter¹, Heather Gladue², Ahmad Kashif¹, Erin Siceloff¹, Victoria Lackey², Cheryl Robertson², Ashley Toci¹ and Leonard Calabrese³, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…
Abstract Number: 1560 • ACR Convergence 2021
A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
Anand Kumthekar¹ and Bibi Ayesha², ¹Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center, Bronx, NY
Background/Purpose: Coronavirus disease (COVID-19) patients can progress to a state of unregulated inflammation called cytokine storm syndrome (CSS). A multi-disciplinary approach is needed to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].